ClinicalTrials.gov
ClinicalTrials.gov Menu

Adjuvant Cetuximab and Chemoradiation in Head and Neck Cancer (ACCRA-HN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00791141
Recruitment Status : Completed
First Posted : November 14, 2008
Last Update Posted : January 23, 2014
Sponsor:
Information provided by (Responsible Party):
Heinrich-Heine University, Duesseldorf

November 13, 2008
November 14, 2008
January 23, 2014
August 2008
April 2013   (Final data collection date for primary outcome measure)
Rate of patients experiencing grade 3/4 acute toxicities not considering grade 3/4 skin tox. outside the radiation portals combined with 2-years disease-free survival rate. [ Time Frame: any toxicities occurring within 90 days post radiation start ]
Same as current
Complete list of historical versions of study NCT00791141 on ClinicalTrials.gov Archive Site
  • Incidence of Loco-regional relapse [ Time Frame: assessment after patient has completed follow-up ]
  • Disease-free survival [ Time Frame: time from start of surgery to the first evidence of loco-regional or distant tumor relapse or death ]
  • Progression-free survival [ Time Frame: from start of surgery to the first observation of disease progression or death ]
  • Overall survival [ Time Frame: censored at the time of last documented efficacy ]
  • The rate of patients with secondary primary neoplasm [ Time Frame: assessment after patient has completed follow-up ]
  • The incidence of late toxicity [ Time Frame: beyond 90 days after start of radiation therapy ]
Same as current
Not Provided
Not Provided
 
Adjuvant Cetuximab and Chemoradiation in Head and Neck Cancer
Multicenter, Open-label Phase II Trial on Post-surgery Chemoradiation in Combination With Cetuximab in Squamous Cell Carcinoma of the Head and Neck With High Risk of Locoregional Recurrence.
This multicenter, open-label, uncontrolled phase II trial evaluates safety and efficacy of post-operative chemoradiation in combination with cetuximab in squamous cell carcinoma of the head and neck.

Advanced squamous cell carcinoma of the head and neck still has a poor prognosis and loco-regional recurrence frequently occurs. Efforts have been made to improve response rates and survival and different therapeutic regimens including concurrent chemo-radiotherapy or sequential chemo-radiotherapy have been developed.

To further increase the outcome of patients with locally advanced SCCHN effective new treatments with minimal toxicities are needed. Molecular targeted agents, which do not demonstrate overlapping toxicities with commonly used chemotherapy agents, have therefore been investigated. The EGFR is widely expressed at high levels in SSCHN and is associated with poor prognosis.

Cetuximab has already been investigated in combination with radiotherapy or chemotherapy in patients with head and neck cancer. The immunoradiotherapy was well tolerated with most of the side effects related to the high dose irradiation. The most common side effects are mucositis and dysphagia. Additionally, skin reactions appear sometimes more frequently in cetuximab administration. Grade 3 to 4 infusion reactions were observed in 3% of the patients treated with cetuximab. Based on the current promising results with RCT in patients with locally advanced head and neck cancer and clinical results with EGFR-antibodies plus RT, the present study was primarily designed to define the acute grade 3/4 toxicity.

We expect to show effective results in reducing the risk of distant metastasis, with administration of an additional six month adjuvant cetuximab treatment, in patient with recurrent SCCHN.

Interventional
Phase 2
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Head and Neck Cancer
Drug: Cetuximab
Loading dose prior to chemoradiotherapy 400 mg/m², followed by every week infusion of 250 mg/m² during chemoradiotherapy. After chemoradiotherapy every 2 week infusions of 500 mg/m² over 6 months.
Other Name: Erbitux
Experimental: Cetuximab
Cetuximab in combination with radiotherapy, cisplatin and 5-FU. After chemoradiotherapy all patients receive a cetuximab maintenance therapy.
Intervention: Drug: Cetuximab
Budach W, Bölke E, Homey B. Severe cutaneous reaction during radiation therapy with concurrent cetuximab. N Engl J Med. 2007 Aug 2;357(5):514-5.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
80
Same as current
September 2013
April 2013   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Signed written informed consent;
  • Males or females between 18 and 70 years of age;
  • Surgically resected squamous cell carcinomas of the hypopharynx, oropharynx, larynx and oral cavity with high risk of locoregional recurrence not more than 6-9 weeks (maximum) ago;
  • To be categorized as high risk patients have to fulfil at least one of the following criteria:

    • R0 - resection <5 mm margin
    • R1 - resection
    • Extracapsular nodal extension;
  • no previous chemotherapy, radiotherapy;
  • Performance status ECOG: 0 - 1;
  • Contraception in male and female patients if of childbearing potential, willingness to use effective contraceptive method for the study duration and 2 months post-dosing;
  • Adequate renal, liver and hematological functions (within maximum 9 weeks until surgery):

    • Adequate bone marrow function: neutrophils > 1.5 x 10^9/L, platelets > 100 x 10^9/L, hemoglobin > 10.0 g/dL
    • Adequate liver function: Bilirubin < 2.0 mg/dL, AST, ALT, AP, γ-GT < 3 x ULN
    • Adequate renal function: creatinine clearance > =60 ml/min
  • No distant metastases;

Exclusion Criteria:

  • Nasopharyngeal carcinoma;
  • R2 resection;
  • Invalid informed consent;
  • Performance Status > 1;
  • Previous chemotherapy or radiotherapy for carcinoma of the head and neck;
  • Prior exposure to EGFR pathway targeting therapy;
  • Other serious illness or medical conditions:

    • Unstable cardiac disease despite treatment, congestive heart failure NYHA grade 3 and 4;
    • Clinically significantly abnormal electrocardiogram (ECG) or left ventricular ejection fraction (LVEF) below the institutional range of the normal
    • Significant neurologic or psychiatric disorders including dementia or seizures;
    • Active uncontrolled infection;
    • Active disseminated intravascular coagulation;
    • Other serious underlying medical conditions which could impair the ability of the patient to participate in the study;
  • Symptomatic peripheral neuropathy National Cancer Institute-Common Toxicity Criteria (NCI-CTC v3.0) grade 2 or ototoxicity grade 2, except if due to trauma or mechanical impairment due to tumor mass;
  • Having participated in another therapeutic clinical trial or any investigational agent in the preceding 30 days;
  • Known allergic/hypersensitivity reaction to any of the components of the treatment;
  • Pregnancy (absence confirmed by serum/urine β-HCG) or breast-feeding;
  • Known drug abuse;
  • Other previous malignancy within 5 years, with exception of a history of a previous basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix;
  • Legal incapacity or limited legal capacity;
  • Sensitivity and incompatibility against 5-Fluorouracil
  • Sensitivity and incompatibility against platinum-compounds
  • Known incompatibilities >grade 3 towards cetuximab
  • expected incompliance of patient (e.g. in case of severe alcohol addiction)
  • Dental evaluation: Pre treatment dental care before start of radiochemotherapy (approximately 8 to 10 days lapse-time is needed for complete recovery before initiation of radiation therapy).
Sexes Eligible for Study: All
18 Years to 70 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Germany
 
 
NCT00791141
ACCRA-HN
Yes
Not Provided
Not Provided
Heinrich-Heine University, Duesseldorf
Heinrich-Heine University, Duesseldorf
Not Provided
Principal Investigator: Wilfried Budach, Prof. Dr. Department of Radiotherapy and Radiological Oncology
Heinrich-Heine University, Duesseldorf
January 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP